Our lead candidate MBS8 is a micelle formulation of a small molecule TLR7 agonist with the unique selling points:

• Administered by the intravenous route to target multiple cancer types
• Novel Mode of Action which is superior to benchmark TLR7/8 agonists due to the micelle formulation
• Targeting the intracellular TLR7 receptor
• Simple and scalable GMP production
• Superior anti-tumor activity as monotherapy and in combination with anti-PD-1, radiotherapy and chemotherapy
• Favourable safety profile